> 95% (by SDS-PAGE)
Human (Homo sapiens)
azide free; unconjugated
Monoclonal Antibody (Mab)
HLA-A2 solubilised by papain_x000D_
Purified by protein-A affinity chromatography
Mouse Monoclonal Antibody against Human HLA-A2, Clone: BB7.2
MHC (Major Histocompatibility Complex) and Related Antigens (Human)
Azide free phosphate buffered saline (PBS), approx. pH 7.4; 0.2 μm filter sterilized.
If you buy Antibodies supplied by Exbio they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.
at the time of upload there has been no data, please, contact us to obtain most recent information on species reactivity and cross reactivity
The antibody BB7.2 recognizes an epitope at the C-terminus of alpha-2 helix and a turn on one of the underlying beta strands within the human HLA-A2 histocompatibility antigen.
Monoclonals of this antigen are available in different clones. Each murine monoclonal anibody has his own affinity specific for the clone. Mouse monoclonal antibodies are purified protein A or G and can be conjugated to FITC for flow cytometry or FACS and can be of different isotypes.
Mouse Monoclonal Antibody against Human HLA-A2, Clone: BB7.2 is transported on blue ice/ice packs and should be stored at temperatures between 1 and 5 degrees Celsius. Do not freeze! Avoid exposing the product to direct light, especially the conjugated antibodies as most conjugates are very sentitive to light.
HLA-A2 (44 kDa) is the most frequent HLA-A allele in human ethnic populations. HLA-A, together with HLA-B and HLA-C, represent human HLA class I major histocompatibility (MHC) antigens. These intrinsic membrane glycoproteins are expressed on nucleated cells and noncovalently associate with an invariant beta2 microglobulin. They carry foreign determinants important for immune recognition by cytotoxic T cells, thus important for anti-viral and anti-tumour defence._x000D_
, *Liang B, Zhu L, Liang Z, Weng X, Lu X, Zhang C, Li H, Wu X: A simplified PCR-SSP method for HLA-A2 subtype in a population of Wuhan, China. Cell Mol Immunol. 2006 Dec;3(6):453-8._x000D_ , *Forero L, Zwirner NW, Fink CW, Fernández-Viña MA, Stastny P: Juvenile arthritis, HLA-A2 and binding of DEK oncogene-peptides. Hum Immunol. 1998 Jul;59(7):443-50. _x000D_ , *Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP: Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol. 2000 Sep;96(3):422-30._x000D_ , *Verdegaal EM, Huinink DB, Hoogstraten C, Marijnissen AK, Gorsira MB, Claas FH, Osanto S: Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient. Hum Immunol. 1999 Dec;60(12):1195-206._x000D_ , *Lee L, Loftus D, Appella E, Margulies DH, Mage M: A recombinant single-chain HLA-A2.1 molecule, with a cis active beta-2-microglobulin domain, is biologically active in peptide binding and antigen presentation. Hum Immunol. 1996 Aug;49(1):28-37._x000D_ , *Barouch D, Davenport M, McMichael A, Reay P: A mAb against HLA-A2 can be influenced both positively and negatively by the associated peptide. Int Immunol. 1995 Oct;7(10):1599-605._x000D_ , *Peoples GE, Goedegebuure PS, Andrews JV, Schoof DD, Eberlein TJ: HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol. 1993 Nov 15;151(10):5481-91._x000D_ , *Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D'Amaro J, Kenemans P, Melief CJ, Kast WM: Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol. 1993 Jun;23(6):1215-9._x000D_ , *Hogan KT, Brown SL: Localization and characterization of serologic epitopes on HLA-A2. Hum Immunol. 1992 Mar;33(3):185-92._x000D_ , *Natali PG, Nicotra MR, Bigotti A, Venturo I, Marcenaro L, Giacomini P, Russo C: Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6719-23._x000D_ , *Santos-Aguado J, Barbosa JA, Biro PA, Strominger JL: Molecular characterization of serologic recognition sites in the human HLA-A2 molecule. J Immunol. 1988 Oct 15;141(8):2811-8."_x000D_ , *Scornik JC: HLA-A2 epitopes recognized by alloantibodies from broadly sensitized patients. Hum Immunol. 1987 Apr;18(4):277-85._x000D_ , *Brenner MB, McLean J, Yang SY, van der Poel JJ, Pious D, Strominger JL: Clonal T lymphocyte recognition of the fine structure of the HLA-A2 molecule. J Immunol. 1985 Jul;135(1):384-90._x000D_ , *Taketani S, Krangel MS, Pious D, Strominger JL: Structural analysis of HLA-A2 antigen from immunoselected mutant 8.6.1: further definition of an HLA-A2-specific serological determinant. J Immunol. 1983 Dec;131(6):2935-8. "_x000D_ , *Krangel MS, Taketani S, Pious D, Strominger JL: HLA-A2 mutants immunoselected in vitro. Definition of residues contributing to an HLA-A2-specific serological determinant. J Exp Med. 1983 Jan 1;157(1):324-36."_x000D_ , *Pious D, Krangel MS, Dixon LL, Parham P, Strominger JL: HLA antigen structural gene mutants selected with an allospecific monoclonal antibody. Proc Natl Acad Sci U S A. 1982 Dec;79(24):7832-6., *Parham P, Brodsky FM: Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol. 1981 Dec;3(4):277-99._x000D_